{"gene":"CCL25","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1997,"finding":"CCL25 (TECK) is produced by thymic dendritic cells and exhibits chemotactic activity for activated macrophages, dendritic cells, and thymocytes in vitro.","method":"Recombinant protein chemotaxis assay; source identification by cell-type-specific expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — original discovery paper with in vitro chemotaxis assay and cellular source identification, foundational and highly cited","pmids":["9285413"],"is_preprint":false},{"year":1999,"finding":"CCL25 binds specifically to the orphan receptor GPR-9-6 (renamed CCR9), inducing intracellular calcium mobilization and in vitro migration of CCR9-transfected cells; no other chemokines tested produced responses via CCR9.","method":"Calcium flux assay and chemotaxis assay in CCR9-transfected HEK293 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in transfected cells with receptor deorphanization; replicated across multiple labs","pmids":["10229797","10498628"],"is_preprint":false},{"year":1999,"finding":"CCL25 (TECK) efficaciously induces chemotaxis of immature CD4+CD8+ double-positive and mature CD4+ and CD8+ single-positive human thymocytes via CCR9.","method":"In vitro chemotaxis assay with primary human thymocytes and CCR9-expressing cell lines","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — direct chemotaxis assay with primary cells; independently replicated","pmids":["10498628"],"is_preprint":false},{"year":2000,"finding":"CCL25 is produced predominantly by thymic epithelial cells (not dendritic cells) and by small intestinal epithelial cells; it chemoattracts both double-positive and single-positive thymocytes via CCR9.","method":"Immunohistochemistry and in vitro migration assays; CCR9 cDNA cloning and localization","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — cell-type source reassignment with IHC and functional migration assays, highly cited","pmids":["10602049"],"is_preprint":false},{"year":2000,"finding":"CCR9 is expressed at high levels on essentially all small intestinal CD4+ and CD8+ T lymphocytes, and CCL25 is expressed selectively by small intestinal crypt epithelium; this CCL25–CCR9 axis mediates selective migration of lymphocytes to the small intestinal mucosa.","method":"Immunohistochemistry; in vitro migration assay; flow cytometry of tissue lymphocytes","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, highly cited, foundational tissue-localization paper","pmids":["10974041"],"is_preprint":false},{"year":2000,"finding":"CCL25 also binds with high affinity to CCX-CKR (provisionally CCR10), a second chemokine receptor, with IC50 <15 nM, as determined by stalkokine adhesion and radiolabeled ligand competition assays.","method":"Stalkokine adhesion assay; radiolabeled ligand binding and competition with >80 chemokines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — systematic in vitro binding assay with >80 chemokines tested; single lab but rigorous methodology","pmids":["10706668"],"is_preprint":false},{"year":2000,"finding":"CCR9 exists as two alternatively spliced isoforms, CCR9A (12 extra N-terminal amino acids) and CCR9B; CCR9A has a lower EC50 for CCL25 and is desensitized at doses that do not silence CCR9B, extending the concentration range over which cells respond to CCL25.","method":"cDNA cloning, calcium flux assay and chemotaxis assay comparing CCR9A vs CCR9B transfectants","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in transfected cells with functional dose-response comparison of two isoforms","pmids":["10640743"],"is_preprint":false},{"year":2001,"finding":"CCR9 engagement by CCL25 activates PI3K-dependent phosphorylation of Akt, GSK-3β, and FKHR, and MAPK; PI3K (but not MAPK) is required for CCR9-mediated chemotaxis. CCL25/CCR9 signaling provides a cell survival signal blocking cycloheximide-induced and partially Fas-mediated apoptosis independently of c-FLIPL.","method":"Chemical inhibitor studies, immunoblotting for phosphorylated proteins, apoptosis assays (PARP cleavage, caspase-3 activation) in MOLT4 cells naturally expressing CCR9","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — multiple signaling pathway dissections with chemical inhibitors and functional readouts in endogenous-receptor-expressing cells","pmids":["11493434"],"is_preprint":false},{"year":2002,"finding":"CCL25 selectively chemoattracts IgA antibody-secreting cells (ASC) from spleen, Peyer's patches, and mesenteric lymph nodes via CCR9; IgG- and IgM-ASC respond poorly. Small intestinal epithelial cells selectively express CCL25, consistent with targeting IgA-producing cells to the gut wall.","method":"In vitro migration/chemotaxis assays with sorted antibody-secreting cells; immunohistochemistry","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — direct chemotaxis assay with multiple ASC populations and controls; highly cited","pmids":["11805153"],"is_preprint":false},{"year":2002,"finding":"CCR9 expression is maintained on CD8αβ+ T cells activated in mesenteric lymph nodes but rapidly downregulated on those activated in peripheral lymph nodes; in vivo neutralization of CCL25 reduced the ability of CCR9+ CD8αβ+ lymphocytes to populate the small-intestinal epithelium.","method":"TCR transgenic T cell transfer model; in vivo antibody neutralization; flow cytometry","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vivo neutralization plus adoptive transfer with defined cellular readout, highly cited","pmids":["12393847"],"is_preprint":false},{"year":2002,"finding":"CCL25–CCR9 signaling is essential for cryptopatch (CP) formation in the gut and the consequent thymus-independent generation of intestinal intraepithelial T lymphocytes (IEL); CD11c+ dendritic stromal cells in CPs express CCL25, and c-kit+ Lin− bone marrow progenitors express CCR9 and migrate in response to CCL25.","method":"CCL25 intrakine transgenic mice (dominant-negative CCL25 signaling); bone marrow reconstitution; RT-PCR; chemotaxis assay","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function (intrakine) with specific anatomical and cellular phenotype, plus functional chemotaxis assay","pmids":["12096027"],"is_preprint":false},{"year":2002,"finding":"Anti-CCL25 antibody administration to neonatal mice reduces CD8αα+TCRγδ+ and CD8αα+TCRαβ+ IEL by ~50%, demonstrating CCL25 is required for maintenance/development of IEL precursors in the small intestine.","method":"In vivo antibody neutralization in neonatal mice; flow cytometry; CCR9 expression analysis on IEL precursors","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo neutralization with specific quantitative cellular phenotype","pmids":["12442331"],"is_preprint":false},{"year":2002,"finding":"CCR9 is expressed on the majority of CD4+CD8+ double-positive thymocytes but not on CD4−CD8− double-negative thymocytes; CD69+ thymocytes show enhanced CCL25-induced migration compared to CD69− thymocytes; TCR stimulation augments CCL25 responsiveness; ~50% of γδTCR+ thymocytes and peripheral γδ T cells express CCR9 and migrate in response to CCL25.","method":"Polyclonal anti-CCR9 antibody generation; flow cytometry; in vitro migration assays of sorted thymocyte subpopulations","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — systematic characterization with validated antibody, multiple cell populations, and functional assays","pmids":["11751956"],"is_preprint":false},{"year":2003,"finding":"CCL25/CCR9-mediated lymphocyte adhesion to small intestinal microvessels is demonstrated in vivo; CCR9 desensitization or anti-CCL25 antibody significantly inhibits LPL adhesion in small (but not large) intestine, including TNF-α-induced adhesion; TNF-α upregulates CCL25 expression in small intestinal lamina propria.","method":"Intravital microscopy; in vivo CCR9 desensitization with CCL25; anti-CCL25 antibody neutralization","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 2 — direct in vivo intravital imaging with specific perturbations; functional consequence demonstrated","pmids":["14592943"],"is_preprint":false},{"year":2004,"finding":"CCL25 is aberrantly expressed on hepatic endothelium in primary sclerosing cholangitis (PSC) and activates α4β7 binding to MAdCAM-1 on hepatic endothelium, thereby recruiting gut-primed CCR9+ T cells to the liver and mediating extra-intestinal inflammation.","method":"Immunohistochemistry; flow cytometry; in vitro adhesion assay under flow conditions","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway defined with multiple methods; highly cited; first demonstration in humans of ectopic CCL25-driven lymphocyte homing","pmids":["15557349"],"is_preprint":false},{"year":2004,"finding":"CCR9/CCL25 signaling promotes induction and function of CD103 on CD8+ intestinal IEL: CCR9-deficient CD8+ T cells show delayed CD103 induction after entry into small intestinal epithelium; CCL25 induces transient, dose-dependent, pertussis toxin-sensitive CD103-mediated adhesion of CD8+ IEL to E-cadherin.","method":"CCR9−/− mice; adoptive transfer; pertussis toxin treatment; adhesion assay to mEFc fusion protein","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with specific phenotype plus functional adhesion assay with pertussis toxin dissection","pmids":["15368288"],"is_preprint":false},{"year":2006,"finding":"CCL25 expression in small intestinal epithelial cells is regulated by caudal-related homeobox (Cdx) transcription factors: Cdx proteins bind to putative Cdx sites in the CCL25 promoter (EMSA), and co-transfection of Cdx-1 or Cdx-2 significantly increases CCL25 promoter activity and endogenous CCL25 mRNA in intestinal cell lines.","method":"Promoter deletion analysis; EMSA; co-transfection/reporter assay; RT-PCR","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — EMSA demonstrating direct protein-DNA binding plus functional reporter assay with cotransfection","pmids":["16517733"],"is_preprint":false},{"year":2006,"finding":"CCL25 and CCL28 redundantly recruit IgA+ plasmablasts to the small intestinal lamina propria after rotavirus infection; combined antibody blockade of both chemokines (but neither alone) prevents IgA+ plasmablast accumulation; CCR9 and α4β7 are coexpressed on IgA+ plasmablasts and both pathways are required.","method":"CCR9 knockout mice; in vivo antibody neutralization (anti-CCL25, anti-CCL28, anti-α4); flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO combined with in vivo neutralization; demonstrates redundancy and pathway cooperation","pmids":["16670280"],"is_preprint":false},{"year":2007,"finding":"CCL25 is required for antigen-dependent accumulation of CCR9high memory-phenotype CD8+ T cells within the small intestinal lamina propria and epithelium, but is dispensable for generating CCR9high memory phenotype in mesenteric lymph nodes.","method":"CCL25−/− mice; TCR-transgenic naive CD8+ T cell transfer; oral antigen sensitization; flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — CCL25 KO mice generated and used in adoptive transfer model with clear dissociation of priming vs. trafficking roles","pmids":["17548595"],"is_preprint":false},{"year":2007,"finding":"CCL25-stimulated α4β1-integrin-mediated adhesion of thymocytes to CS-1/fibronectin and VCAM-1 requires activation of Rac and Rap1 GTPases; downstream effectors WAVE2 and RAPL (but not RIAM) are required for efficient CCL25-triggered integrin-dependent adhesion; Rac-WAVE2 drives post-adhesion actin-dependent spreading.","method":"GTPase activity assays; shRNA knockdown of WAVE2, RAPL, RIAM; adhesion assays on CS-1/FN and VCAM-1; Molt-4 CCR9+/α4β1+ cell line","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 — mechanistic pathway dissection with multiple shRNA knockdowns and functional adhesion readouts","pmids":["17510295"],"is_preprint":false},{"year":2008,"finding":"CCL25 and CCL28 both trigger α4β7-dependent lymphocyte arrest on immobilized MAdCAM-1 under shear flow conditions, but have no effect on α4β1/VCAM-1-mediated adhesion, demonstrating selective activation of α4β7 integrin.","method":"Flow-based adhesion assay with immobilized chemokines on MAdCAM-1 and VCAM-1; integrin-blocking antibodies","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution under physiological shear with selective integrin pathway dissection","pmids":["18308860"],"is_preprint":false},{"year":2008,"finding":"Androgen withdrawal increases thymic epithelial cell (TEC) production of CCL25, particularly by UEA+ TEC; blockade of CCL25 abrogates the effects of castration by impairing early thymic progenitor (ETP) entry, retarding thymocyte development, and limiting thymic size increase.","method":"Castration model; CCL25 antibody blockade; adoptive transfer of quantified precursors; flow cytometry of ETP and TEC populations","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo blockade with specific mechanistic cellular phenotypes; defines CCL25 as downstream effector of androgen signaling in thymus","pmids":["18694999"],"is_preprint":false},{"year":2008,"finding":"CCR9-CCL25 interactions promote migration and invasion of cutaneous melanoma cells expressing CCR9 toward CCL25 gradients in a CCR9-dependent manner (blocked by anti-CCR9 antibody or CCR9 siRNA); CCR9+ melanoma cells also express α4β1 integrin, suggesting cooperative adhesion mechanisms.","method":"In vitro migration and invasion assays; anti-CCR9 antibody and siRNA knockdown; flow cytometry; RT-PCR","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — receptor knockdown with two orthogonal methods (antibody and siRNA) with functional migration readouts","pmids":["18245522"],"is_preprint":false},{"year":2009,"finding":"P-selectin and CCL25 are periodically co-expressed in the thymus and both are essential components of the thymic gate-keeping mechanism for T-cell progenitor (TCP) importation; sphingosine-1-phosphate (S1P) from peripheral lymphocytes feeds back to regulate thymic P-selectin expression and TCP receptivity.","method":"Periodic expression analysis; P-selectin ligand mutant mice; competitive TCP reconstitution; S1P manipulation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic models plus functional reconstitution experiments defining CCL25 role in thymic gating","pmids":["19289576"],"is_preprint":false},{"year":2009,"finding":"Ezrin is a key molecule in CCL25-induced MOLT4 cell polarization and invasive behavior: CCL25 induces pseudopodium formation and ERM translocation from cytoplasm to cell membrane; ezrin silencing by miRNA impairs CCL25-induced cell polarization and invasion.","method":"miRNA-mediated ezrin silencing; confocal microscopy of ERM translocation; invasion assay","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2 — gene knockdown with functional readout; single lab","pmids":["20036004"],"is_preprint":false},{"year":2010,"finding":"CCR9-CCL25 signaling activates PI3K/Akt and ERK1/2 pathways in prostate cancer cells to upregulate antiapoptotic proteins (PI3K, AKT, ERK1/2, GSK-3β) and suppress caspase-3 activation; PI3K inhibitor wortmannin abrogates these effects; in vivo tumor burden is reduced by CCL25 neutralizing antibodies combined with etoposide.","method":"PI3K inhibitor (wortmannin); anti-CCR9 monoclonal antibodies; caspase-3 assay; in vivo mouse xenograft","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro pathway inhibition plus in vivo xenograft; single lab","pmids":["20127861"],"is_preprint":false},{"year":2010,"finding":"CCL25 induces RhoA activation and MLC phosphorylation (RhoA-ROCK-MLC axis) in MOLT4 cells; C3 exoenzyme and ROCK inhibitor Y-27632 block CCL25-induced cell migration and chemotaxis.","method":"GTPase activity assay; pharmacological inhibitors (C3 exoenzyme, Y-27632); migration and chemotaxis assay","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2 — pathway inhibition with multiple agents and functional readouts; single lab","pmids":["20855113"],"is_preprint":false},{"year":2010,"finding":"CCL25 stimulates migration of human subchondral mesenchymal progenitor cells in a CCR9-dependent fashion, as demonstrated by chemotaxis assay; these progenitors express CCR9 mRNA and protein.","method":"96-well chemotaxis assay; gene expression analysis (real-time PCR); immunohistochemistry for CCR9","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 3 — functional chemotaxis assay with receptor expression validation; single lab","pmids":["20709179"],"is_preprint":false},{"year":2011,"finding":"CCL25 promotes breast cancer cell (MDA-MB-231) migration and invasion through CCR9; neutralizing CCR9-CCL25 interactions impairs migration and invasion; CCL25 enhances expression of active MMP-1, -9, -11, and -13 in a CCR9-dependent fashion.","method":"Migration and invasion assays; anti-CCR9 neutralization; ELISA for active MMP proteins","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor neutralization with functional readouts and downstream MMP measurement; single lab","pmids":["21344163"],"is_preprint":false},{"year":2011,"finding":"CCL25/CCR9 interactions regulate colitis in the large intestine: CCR9−/− mice are more susceptible to DSS colitis, with accumulation of activated macrophages, elevated Th1/Th17 cytokines, and altered DC subset balance in mesenteric lymph nodes during recovery.","method":"CCR9−/− mice; DSS colitis model; flow cytometry; cytokine quantification (mRNA and protein); IBD scoring","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple mechanistic readouts demonstrating CCL25/CCR9 role in DC subset balance and cytokine regulation","pmids":["21283540"],"is_preprint":false},{"year":2012,"finding":"Multiple myeloma cells produce CCL25 as a major chemoattractant for bone marrow mesenchymal stromal cells (MSCs); CCL25-recruited MSCs favor myeloma cell proliferation and protect against apoptosis by enhancing AKT and ERK activity and upregulating CyclinD2, CDK4, and Bcl-XL.","method":"In vitro and in vivo migration assays; CCL25 neutralization; co-culture proliferation/apoptosis assays; western blotting; intrafemoral coengraftment","journal":"Stem cells","confidence":"High","confidence_rationale":"Tier 2 — CCL25 identified as chemoattractant by neutralization, pathway activation characterized, and in vivo validation","pmids":["22102554"],"is_preprint":false},{"year":2013,"finding":"CCL25-induced drug resistance in T-ALL MOLT4 cells involves phosphorylated ERM (p-ERM) serving as a scaffold linking P-glycoprotein (P-gp) to F-actin; ERM silencing by shRNA releases P-gp from F-actin and restores drug sensitivity.","method":"shRNA-mediated ERM knockdown; co-immunoprecipitation of p-ERM, P-gp, and F-actin; P-gp functional assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus shRNA knockdown with functional drug-resistance readout; mechanistic scaffolding role defined","pmids":["23326330"],"is_preprint":false},{"year":2014,"finding":"CCL25-stimulated endometrial stromal cell-derived Treg differentiation is mediated via AKT/STAT3 signaling; ESC/macrophage-derived TECK induces Treg differentiation, increases IL-10, TGF-β, and CD73 expression, and represses Treg apoptosis (reducing Fas/FasL); anti-TECK neutralizing antibodies inhibit these effects.","method":"Co-culture experiments; AKT/STAT3 signaling analysis; anti-TECK neutralizing antibodies; in vitro and in vivo trials","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway identified with neutralizing antibody validation and in vivo confirmation; single lab","pmids":["25275597"],"is_preprint":false},{"year":2017,"finding":"CCL25 induces Wnt5a expression in MOLT4 T-ALL cells via promotion of PKC expression and activation; Wnt5a then promotes cell migration, invasion, actin polarization, and lamellipodia/filopodia formation via PI3K/Akt-RhoA pathway; PI3K/Akt or RhoA knockdown/inhibition rescues these effects.","method":"Transwell invasion/migration assays; western blotting; siRNA and inhibitor knockdown of PI3K/Akt and RhoA; confocal and scanning electron microscopy; mouse xenograft","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with multiple inhibitors/knockdowns and in vivo validation; single lab","pmids":["28380463"],"is_preprint":false},{"year":2020,"finding":"CCL25 acts via the Gαi-coupled receptor CCR9 to inhibit glucose-induced insulin secretion in a concentration-dependent manner, enhance cytokine-induced apoptosis, and reduce cAMP levels in human and mouse islets; these effects are blocked by the CCR9 antagonist vercirnon.","method":"Insulin secretion assay; cAMP accumulation assay; apoptosis assay in primary human and mouse islets; CCR9 antagonist (vercirnon)","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 1 — in vitro assays on primary human and mouse islets with pharmacological antagonist validation; multiple functional readouts","pmids":["33058852"],"is_preprint":false},{"year":2021,"finding":"CCL25 stimulates RA FLS and monocyte migration via p38 and ERK phosphorylation; CCL25 polarizes RA monocytes into non-traditional M1 macrophages producing IL-8 and CCL2 via p38 and ERK cascades; CCL25-induced osteoclastogenesis is regulated by RANK, cathepsin K, and TNF-α but not RANKL.","method":"p38 and ERK inhibitors; flow cytometry; cytokine ELISA; osteoclast differentiation assay in RA synovial tissue/cells","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway defined with kinase inhibitors and functional differentiation assays; single lab","pmids":["33347617"],"is_preprint":false},{"year":2022,"finding":"CCL25 promotes increased endothelial permeability by reducing tight junction protein expression via activation of the P38 MAPK pathway; NF-κB inhibition in HPMECs decreases CCL25 expression; recombinant CCL25 increases cell permeability and inflammatory cytokine expression.","method":"LPS-stimulated HPMECs; TEER measurement; FITC-fluorescence intensity; luciferase assays; chromatin immunoprecipitation; P38 MAPK pathway analysis","journal":"Infection and drug resistance","confidence":"Medium","confidence_rationale":"Tier 1-2 — ChIP and luciferase assays for NF-κB regulation plus functional permeability assays; single lab","pmids":["35782530"],"is_preprint":false}],"current_model":"CCL25 is a CC chemokine produced constitutively by thymic epithelial cells and small intestinal crypt epithelium (regulated by Cdx transcription factors and NF-κB) that acts as the exclusive ligand for CCR9 (a Gαi-coupled GPCR existing as alternatively spliced CCR9A/B isoforms with different ligand sensitivities), activating PI3K/Akt, p38/ERK MAPK, and Rac/Rap1-GTPase signaling to drive chemotaxis, α4β7- and α4β1-integrin-dependent adhesion to MAdCAM-1/VCAM-1, cell survival, osteoclastogenesis, and cancer cell invasion, while its tissue-restricted expression pattern makes it the master organizer of lymphocyte homing to the small intestine and thymus."},"narrative":{"teleology":[{"year":1997,"claim":"The discovery of TECK (CCL25) as a thymus-expressed chemokine with chemotactic activity for macrophages, dendritic cells, and thymocytes established the existence of a tissue-restricted chemokine potentially governing thymic cell trafficking.","evidence":"Recombinant protein chemotaxis assay with primary immune cell populations","pmids":["9285413"],"confidence":"High","gaps":["Cognate receptor unknown","In vivo role undemonstrated","Molecular mechanism of chemotaxis undetermined"]},{"year":1999,"claim":"Identification of GPR-9-6 (CCR9) as the specific receptor for CCL25 resolved the signaling entry point, showing exclusive ligand–receptor pairing with calcium mobilization and chemotaxis, and defined CCL25 as active on both immature double-positive and mature single-positive thymocytes.","evidence":"Receptor deorphanization via calcium flux and chemotaxis in CCR9-transfected HEK293 cells; primary human thymocyte migration assays","pmids":["10229797","10498628"],"confidence":"High","gaps":["In vivo requirement not demonstrated","Downstream signaling cascade uncharacterized","Additional receptor interactions unknown"]},{"year":2000,"claim":"Mapping CCL25 production to thymic epithelial cells and small intestinal crypt epithelium, combined with finding high CCR9 expression on all small intestinal T cells, established the CCL25–CCR9 axis as a dual tissue-homing system for thymus and gut; discovery of CCR9A/B splice variants and CCX-CKR binding expanded the receptor biology.","evidence":"Immunohistochemistry, flow cytometry of tissue lymphocytes, cDNA cloning with dose-response comparison of CCR9 isoforms, radiolabeled ligand binding to CCX-CKR","pmids":["10602049","10974041","10640743","10706668"],"confidence":"High","gaps":["In vivo genetic loss-of-function evidence lacking","Functional significance of CCX-CKR binding unclear","Transcriptional regulation of CCL25 expression unknown"]},{"year":2001,"claim":"Dissection of intracellular signaling revealed that CCL25–CCR9 activates PI3K/Akt (required for chemotaxis) and MAPK pathways, and provides anti-apoptotic survival signals blocking cycloheximide- and partially Fas-mediated cell death, establishing CCL25 as both a migratory and survival factor.","evidence":"Chemical inhibitor studies, phospho-protein immunoblotting, and apoptosis assays (PARP cleavage, caspase-3) in endogenous CCR9-expressing MOLT4 cells","pmids":["11493434"],"confidence":"High","gaps":["GTPase-level effectors for adhesion not identified","Survival mechanism in primary cells not confirmed","Relative contribution of PI3K vs MAPK to different outcomes unclear"]},{"year":2002,"claim":"In vivo studies using antibody neutralization, CCL25-intrakine transgenic mice, and CCR9 expression profiling demonstrated that CCL25 is required for IgA-ASC recruitment to the gut, IEL maintenance and development, cryptopatch formation, and CD8+ T cell homing to the small intestinal epithelium.","evidence":"In vivo anti-CCL25 antibody neutralization in neonatal and adult mice; CCL25-intrakine transgenic model; TCR-transgenic adoptive transfer; sorted ASC chemotaxis assays","pmids":["11805153","12393847","12096027","12442331","11751956"],"confidence":"High","gaps":["CCL25 complete knockout mouse phenotype not yet reported at this point","Redundancy with other gut-homing chemokines not fully delineated","Role in thymic progenitor entry not directly tested"]},{"year":2004,"claim":"CCL25 was shown to activate α4β7 integrin binding to MAdCAM-1 on hepatic endothelium in primary sclerosing cholangitis, establishing the first ectopic CCL25 disease mechanism, and to promote CD103-mediated IEL adhesion to E-cadherin in a pertussis toxin-sensitive manner, defining an additional integrin-activation pathway.","evidence":"Flow-based adhesion assay on human hepatic endothelium; CCR9−/− adoptive transfer; pertussis toxin treatment with adhesion readout","pmids":["15557349","15368288"],"confidence":"High","gaps":["Whether ectopic CCL25 expression occurs in other inflammatory liver diseases unclear","Signaling intermediates linking CCR9 to CD103 activation not identified"]},{"year":2006,"claim":"Transcriptional control of CCL25 was established by showing that Cdx-1 and Cdx-2 homeodomain proteins directly bind the CCL25 promoter to drive its intestinal expression, and functional redundancy with CCL28 was demonstrated for IgA plasmablast recruitment after rotavirus infection.","evidence":"EMSA, promoter-reporter assays, cotransfection in intestinal cell lines; CCR9-KO mice and combined anti-CCL25/anti-CCL28 antibody blockade","pmids":["16517733","16670280"],"confidence":"High","gaps":["Factors governing thymic CCL25 transcription not identified","Whether Cdx regulation is direct in vivo (ChIP-seq) not shown"]},{"year":2007,"claim":"The GTPase effector pathway downstream of CCR9 was mapped: CCL25 activates Rac and Rap1 to drive α4β1-integrin adhesion to VCAM-1/fibronectin via WAVE2 and RAPL effectors respectively, and CCL25-KO mice showed that CCL25 is required for gut accumulation but not priming of CCR9-high memory CD8+ T cells.","evidence":"shRNA knockdown of WAVE2/RAPL/RIAM with adhesion assays; CCL25−/− mice with oral antigen sensitization and adoptive transfer","pmids":["17510295","17548595"],"confidence":"High","gaps":["Whether Rac-WAVE2 and Rap1-RAPL pathways are simultaneously or sequentially engaged unknown","Role of CCL25 in memory T cell survival in situ not addressed"]},{"year":2008,"claim":"CCL25 was identified as the effector linking androgen withdrawal to enhanced thymic progenitor entry, and was shown to selectively trigger α4β7-dependent (but not α4β1-dependent) lymphocyte arrest under shear flow, while CCR9–CCL25 signaling was found to drive melanoma cell migration and invasion.","evidence":"Castration model with CCL25 antibody blockade and ETP quantification; flow-based adhesion reconstitution with MAdCAM-1/VCAM-1; anti-CCR9 antibody and siRNA in melanoma invasion assays","pmids":["18694999","18308860","18245522"],"confidence":"High","gaps":["Mechanism of selectivity for α4β7 over α4β1 under flow not defined","In vivo melanoma metastasis not tested with CCL25 perturbation"]},{"year":2009,"claim":"CCL25 was integrated into a periodic thymic gating model where its co-expression with P-selectin controls cyclical T-cell progenitor importation, and ezrin was identified as a cytoskeletal scaffold mediating CCL25-induced cell polarization and invasion.","evidence":"Periodic expression analysis with genetic models and competitive TCP reconstitution; miRNA-mediated ezrin silencing with confocal microscopy and invasion assay","pmids":["19289576","20036004"],"confidence":"High","gaps":["Molecular mechanism linking S1P feedback to CCL25 periodicity not established","ERM role confirmed only in MOLT4 cells, not primary lymphocytes"]},{"year":2010,"claim":"Cancer biology studies extended CCL25–CCR9 survival signaling to prostate cancer (PI3K/Akt/ERK-dependent anti-apoptosis reversed by wortmannin and anti-CCL25 antibodies in xenografts), and the RhoA-ROCK-MLC axis was identified as required for CCL25-driven migration.","evidence":"PI3K inhibitor and in vivo xenograft with CCL25 neutralization; GTPase assays and ROCK inhibitor (Y-27632) in chemotaxis","pmids":["20127861","20855113"],"confidence":"Medium","gaps":["Clinical relevance of CCR9-CCL25 axis in prostate cancer not validated in patient cohorts","Interplay between RhoA and Rac pathways downstream of CCR9 not resolved"]},{"year":2011,"claim":"CCL25 was shown to promote breast cancer invasion through CCR9-dependent upregulation of active MMPs (MMP-1, -9, -11, -13), while CCR9-KO mice revealed a protective role for the CCL25–CCR9 axis in colitis recovery by regulating DC subset balance and limiting Th1/Th17 cytokine production.","evidence":"Migration/invasion assays with anti-CCR9 neutralization and MMP ELISA; DSS colitis in CCR9−/− mice with flow cytometry and cytokine quantification","pmids":["21344163","21283540"],"confidence":"High","gaps":["Mechanism connecting CCR9 signaling to MMP transcription not defined","Whether CCR9-KO colitis phenotype reflects loss of CCL25-responsive regulatory cells specifically not resolved"]},{"year":2012,"claim":"Myeloma cells were found to produce CCL25 as a paracrine chemoattractant for bone marrow mesenchymal stromal cells, which in turn enhance myeloma proliferation and survival via AKT/ERK, establishing a CCL25-driven stromal niche feedback loop.","evidence":"CCL25 neutralization in migration and co-culture assays; intrafemoral coengraftment; western blotting","pmids":["22102554"],"confidence":"High","gaps":["Contribution of CCL25 relative to other MSC chemoattractants in myeloma bone marrow not quantified","Therapeutic window for CCL25 blockade in myeloma not explored"]},{"year":2013,"claim":"A scaffolding mechanism for CCL25-induced drug resistance was defined: phosphorylated ERM proteins link P-glycoprotein to F-actin in T-ALL cells, and ERM silencing disrupts this complex and restores drug sensitivity.","evidence":"Co-immunoprecipitation of p-ERM/P-gp/F-actin; shRNA-mediated ERM knockdown with P-gp functional assay in MOLT4 cells","pmids":["23326330"],"confidence":"High","gaps":["Relevance of ERM-P-gp scaffolding to primary patient T-ALL cells not tested","Whether CCL25 directly phosphorylates ERM or acts indirectly not determined"]},{"year":2017,"claim":"CCL25 was found to induce Wnt5a expression via PKC in T-ALL cells, with Wnt5a then driving migration and invasion through PI3K/Akt-RhoA, revealing a secondary autocrine/paracrine amplification loop for CCL25-induced motility.","evidence":"siRNA and inhibitor knockdowns of PI3K/Akt and RhoA; western blotting for PKC and Wnt5a; confocal and SEM; mouse xenograft","pmids":["28380463"],"confidence":"Medium","gaps":["Wnt5a induction by CCL25 not confirmed outside MOLT4/T-ALL cells","Whether Wnt5a pathway operates in normal thymocyte migration unknown"]},{"year":2020,"claim":"An unexpected endocrine role for CCL25 was established: CCL25 acts via Gαi-coupled CCR9 on pancreatic islet cells to inhibit glucose-stimulated insulin secretion by reducing cAMP, an effect blocked by the CCR9 antagonist vercirnon.","evidence":"Insulin secretion, cAMP, and apoptosis assays in primary human and mouse islets with pharmacological CCR9 antagonist","pmids":["33058852"],"confidence":"High","gaps":["In vivo metabolic phenotype of CCL25 or CCR9 deficiency not reported","Source of CCL25 reaching islets in vivo not identified"]},{"year":2021,"claim":"CCL25 was shown to drive inflammatory processes in rheumatoid arthritis by stimulating FLS and monocyte migration via p38/ERK, polarizing monocytes into M1-like macrophages, and inducing osteoclastogenesis through a RANKL-independent, RANK/cathepsin K/TNF-α-dependent mechanism.","evidence":"p38 and ERK inhibitors; osteoclast differentiation assay; cytokine ELISA in RA synovial tissue-derived cells","pmids":["33347617"],"confidence":"Medium","gaps":["RANKL-independent osteoclastogenesis by CCL25 not confirmed in other systems","Therapeutic relevance of CCR9 blockade in RA not tested in vivo"]},{"year":2022,"claim":"NF-κB was identified as a direct transcriptional regulator of CCL25 in endothelial cells, and CCL25 was shown to increase endothelial permeability by reducing tight junction proteins via P38 MAPK, linking CCL25 to vascular barrier dysfunction.","evidence":"Chromatin immunoprecipitation and luciferase assays for NF-κB binding; TEER and FITC permeability assays; P38 pathway analysis in LPS-stimulated HPMECs","pmids":["35782530"],"confidence":"Medium","gaps":["In vivo vascular permeability changes from CCL25 not demonstrated","Relationship between NF-κB-driven endothelial CCL25 and Cdx-driven intestinal CCL25 not explored"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CCL25–CCR9 interaction and selective integrin activation, the full physiological consequence of CCX-CKR/ACKR4 scavenging of CCL25, the in vivo metabolic impact of islet CCR9 signaling, and whether CCL25-targeted therapies (e.g., vercirnon) can selectively modulate gut homing without compromising thymic function.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of CCL25–CCR9 complex","CCX-CKR/ACKR4 functional role in CCL25 gradient shaping not established in vivo","Tissue-specific therapeutic targeting strategies untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,4,8,22]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,7,34]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,3,4,8,13]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,9,11,12,14,17,18,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,7,19,25,26,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,21,23]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,25,34]}],"complexes":[],"partners":["CCR9","ACKR4","ITGA4","ITGB7","ITGB1","EZR","MADCAM1"],"other_free_text":[]},"mechanistic_narrative":"CCL25 (TECK) is a CC chemokine that functions as the principal ligand for CCR9 to orchestrate lymphocyte trafficking to the thymus and small intestine, governing T-cell development, intestinal intraepithelial lymphocyte maintenance, and IgA-producing cell recruitment. Constitutively produced by thymic epithelial cells and small intestinal crypt epithelium under transcriptional control of Cdx homeodomain proteins and NF-κB, CCL25 binds CCR9 (a Gαi-coupled receptor with two alternatively spliced isoforms that extend the ligand concentration–response range) and also binds the atypical receptor CCX-CKR [PMID:10602049, PMID:10974041, PMID:16517733, PMID:10706668, PMID:10640743, PMID:35782530]. Engagement of CCR9 activates PI3K/Akt, p38/ERK MAPK, and Rac/Rap1 GTPase cascades that drive chemotaxis, α4β7-integrin–dependent arrest on MAdCAM-1 under shear flow, α4β1-mediated adhesion to VCAM-1/fibronectin, anti-apoptotic signaling, and CD103-dependent epithelial retention of intraepithelial lymphocytes [PMID:11493434, PMID:17510295, PMID:18308860, PMID:15368288, PMID:20855113]. Beyond immune homeostasis, CCL25–CCR9 signaling promotes cancer cell migration and invasion through MMP upregulation and Wnt5a/RhoA pathways, drives osteoclastogenesis via p38/ERK independently of RANKL, and inhibits glucose-stimulated insulin secretion by reducing cAMP in pancreatic islets [PMID:18245522, PMID:21344163, PMID:28380463, PMID:33347617, PMID:33058852]."},"prefetch_data":{"uniprot":{"accession":"O15444","full_name":"C-C motif chemokine 25","aliases":["Chemokine TECK","Small-inducible cytokine A25","Thymus-expressed chemokine"],"length_aa":150,"mass_kda":16.6,"function":"Potentially involved in T-cell development. Recombinant protein shows chemotactic activity on thymocytes, macrophages, THP-1 cells, and dendritics cells but is inactive on peripheral blood lymphocytes and neutrophils. Binds to CCR9. Isoform 2 is an antagonist of isoform 1. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O15444/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL25","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL25","total_profiled":1310},"omim":[{"mim_id":"618806","title":"T-CELL LYMPHOPENIA, INFANTILE, WITH OR WITHOUT NAIL DYSTROPHY, AUTOSOMAL DOMINANT; TLIND","url":"https://www.omim.org/entry/618806"},{"mim_id":"613806","title":"CHOLANGITIS, PRIMARY SCLEROSING; PSC","url":"https://www.omim.org/entry/613806"},{"mim_id":"608529","title":"FIBRILLIN 3; FBN3","url":"https://www.omim.org/entry/608529"},{"mim_id":"606065","title":"ATYPICAL CHEMOKINE RECEPTOR 4; ACKR4","url":"https://www.omim.org/entry/606065"},{"mim_id":"604738","title":"CHEMOKINE, CC MOTIF, RECEPTOR 9; CCR9","url":"https://www.omim.org/entry/604738"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":547.3},{"tissue":"lymphoid tissue","ntpm":718.3}],"url":"https://www.proteinatlas.org/search/CCL25"},"hgnc":{"alias_symbol":["TECK","Ckb15"],"prev_symbol":["SCYA25"]},"alphafold":{"accession":"O15444","domains":[{"cath_id":"2.40.50.40","chopping":"30-105","consensus_level":"high","plddt":89.5141,"start":30,"end":105}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15444","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15444-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15444-F1-predicted_aligned_error_v6.png","plddt_mean":70.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL25","jax_strain_url":"https://www.jax.org/strain/search?query=CCL25"},"sequence":{"accession":"O15444","fasta_url":"https://rest.uniprot.org/uniprotkb/O15444.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15444/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15444"}},"corpus_meta":[{"pmid":"10974041","id":"PMC_10974041","title":"Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10974041","citation_count":493,"is_preprint":false},{"pmid":"10602049","id":"PMC_10602049","title":"The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10602049","citation_count":292,"is_preprint":false},{"pmid":"12393847","id":"PMC_12393847","title":"CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12393847","citation_count":273,"is_preprint":false},{"pmid":"15557349","id":"PMC_15557349","title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.","date":"2004","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15557349","citation_count":251,"is_preprint":false},{"pmid":"9285413","id":"PMC_9285413","title":"TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9285413","citation_count":225,"is_preprint":false},{"pmid":"11805153","id":"PMC_11805153","title":"The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11805153","citation_count":159,"is_preprint":false},{"pmid":"10706668","id":"PMC_10706668","title":"Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10706668","citation_count":154,"is_preprint":false},{"pmid":"10229797","id":"PMC_10229797","title":"Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10229797","citation_count":147,"is_preprint":false},{"pmid":"21283540","id":"PMC_21283540","title":"CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21283540","citation_count":120,"is_preprint":false},{"pmid":"18245522","id":"PMC_18245522","title":"Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18245522","citation_count":118,"is_preprint":false},{"pmid":"17101325","id":"PMC_17101325","title":"Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17101325","citation_count":114,"is_preprint":false},{"pmid":"20709179","id":"PMC_20709179","title":"Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells.","date":"2010","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/20709179","citation_count":95,"is_preprint":false},{"pmid":"22102554","id":"PMC_22102554","title":"Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.","date":"2012","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/22102554","citation_count":87,"is_preprint":false},{"pmid":"11751956","id":"PMC_11751956","title":"Characterization of CCR9 expression and CCL25/thymus-expressed chemokine responsiveness during T cell development: CD3(high)CD69+ thymocytes and gammadeltaTCR+ thymocytes preferentially respond to CCL25.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11751956","citation_count":87,"is_preprint":false},{"pmid":"19289576","id":"PMC_19289576","title":"Thymic progenitor homing and lymphocyte homeostasis are linked via S1P-controlled expression of thymic P-selectin/CCL25.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19289576","citation_count":85,"is_preprint":false},{"pmid":"25275597","id":"PMC_25275597","title":"CD4+Foxp3+ regulatory T cell differentiation mediated by endometrial stromal cell-derived TECK promotes the growth and invasion of endometriotic lesions.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25275597","citation_count":84,"is_preprint":false},{"pmid":"26873648","id":"PMC_26873648","title":"Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity.","date":"2016","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/26873648","citation_count":82,"is_preprint":false},{"pmid":"16670280","id":"PMC_16670280","title":"Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA+ plasmablast recruitment to the intestinal lamina propria after rotavirus infection.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16670280","citation_count":81,"is_preprint":false},{"pmid":"11981810","id":"PMC_11981810","title":"Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11981810","citation_count":80,"is_preprint":false},{"pmid":"15368288","id":"PMC_15368288","title":"CCL25/CCR9 promotes the induction and function of CD103 on intestinal intraepithelial lymphocytes.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15368288","citation_count":80,"is_preprint":false},{"pmid":"17548595","id":"PMC_17548595","title":"Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17548595","citation_count":80,"is_preprint":false},{"pmid":"34490243","id":"PMC_34490243","title":"The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34490243","citation_count":78,"is_preprint":false},{"pmid":"18439426","id":"PMC_18439426","title":"Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease.","date":"2008","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18439426","citation_count":76,"is_preprint":false},{"pmid":"32064335","id":"PMC_32064335","title":"Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32064335","citation_count":74,"is_preprint":false},{"pmid":"21344163","id":"PMC_21344163","title":"CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21344163","citation_count":74,"is_preprint":false},{"pmid":"14592943","id":"PMC_14592943","title":"Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa.","date":"2003","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14592943","citation_count":70,"is_preprint":false},{"pmid":"10498628","id":"PMC_10498628","title":"TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10498628","citation_count":66,"is_preprint":false},{"pmid":"18501472","id":"PMC_18501472","title":"Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13.","date":"2008","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18501472","citation_count":65,"is_preprint":false},{"pmid":"23932985","id":"PMC_23932985","title":"Recombinant TNFα as oral vaccine adjuvant protects European sea bass against vibriosis: insights into the role of the CCL25/CCR9 axis.","date":"2013","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23932985","citation_count":64,"is_preprint":false},{"pmid":"18694999","id":"PMC_18694999","title":"CCL25 increases thymopoiesis after androgen withdrawal.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18694999","citation_count":62,"is_preprint":false},{"pmid":"18308860","id":"PMC_18308860","title":"CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow.","date":"2008","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18308860","citation_count":60,"is_preprint":false},{"pmid":"17158094","id":"PMC_17158094","title":"Expression of Dll4 and CCL25 in Foxn1-negative epithelial cells in the post-natal thymus.","date":"2006","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17158094","citation_count":59,"is_preprint":false},{"pmid":"17653288","id":"PMC_17653288","title":"Commensal bacteria and expression of two major intestinal chemokines, TECK/CCL25 and MEC/CCL28, and their receptors.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17653288","citation_count":56,"is_preprint":false},{"pmid":"11493434","id":"PMC_11493434","title":"Blocking of c-FLIP(L)--independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11493434","citation_count":52,"is_preprint":false},{"pmid":"28622456","id":"PMC_28622456","title":"Increased CCL25 and T Helper Cells Expressing CCR9 in the Salivary Glands of Patients With Primary Sjögren's Syndrome: Potential New Axis in Lymphoid Neogenesis.","date":"2017","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28622456","citation_count":52,"is_preprint":false},{"pmid":"16517733","id":"PMC_16517733","title":"Functional characterization of the CCL25 promoter in small intestinal epithelial cells suggests a regulatory role for caudal-related homeobox (Cdx) transcription factors.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16517733","citation_count":50,"is_preprint":false},{"pmid":"23326330","id":"PMC_23326330","title":"Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23326330","citation_count":47,"is_preprint":false},{"pmid":"21539750","id":"PMC_21539750","title":"CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.","date":"2011","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21539750","citation_count":47,"is_preprint":false},{"pmid":"20127861","id":"PMC_20127861","title":"CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20127861","citation_count":47,"is_preprint":false},{"pmid":"20649989","id":"PMC_20649989","title":"CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.","date":"2010","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20649989","citation_count":47,"is_preprint":false},{"pmid":"20738854","id":"PMC_20738854","title":"Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation.","date":"2010","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20738854","citation_count":46,"is_preprint":false},{"pmid":"20477631","id":"PMC_20477631","title":"Role of CCL25/CCR9 in immune homeostasis and disease.","date":"2006","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20477631","citation_count":46,"is_preprint":false},{"pmid":"10640743","id":"PMC_10640743","title":"CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10640743","citation_count":45,"is_preprint":false},{"pmid":"32401349","id":"PMC_32401349","title":"CCR9 and CCL25: A review of their roles in tumor promotion.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32401349","citation_count":44,"is_preprint":false},{"pmid":"12442331","id":"PMC_12442331","title":"Involvement of CCL25 (TECK) in the generation of the murine small-intestinal CD8alpha alpha+CD3+ intraepithelial lymphocyte compartment.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12442331","citation_count":44,"is_preprint":false},{"pmid":"19003934","id":"PMC_19003934","title":"Human IgA-secreting cells induced by intestinal, but not systemic, immunization respond to CCL25 (TECK) and CCL28 (MEC).","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19003934","citation_count":42,"is_preprint":false},{"pmid":"12096027","id":"PMC_12096027","title":"Pivotal role of CCL25 (TECK)-CCR9 in the formation of gut cryptopatches and consequent appearance of intestinal intraepithelial T lymphocytes.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12096027","citation_count":42,"is_preprint":false},{"pmid":"25691296","id":"PMC_25691296","title":"CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25691296","citation_count":42,"is_preprint":false},{"pmid":"25296976","id":"PMC_25296976","title":"CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25296976","citation_count":42,"is_preprint":false},{"pmid":"16839611","id":"PMC_16839611","title":"Expression of TECK/CCL25 and MEC/CCL28 chemokines and their respective receptors CCR9 and CCR10 in porcine mucosal tissues.","date":"2006","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/16839611","citation_count":40,"is_preprint":false},{"pmid":"20504763","id":"PMC_20504763","title":"Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20504763","citation_count":39,"is_preprint":false},{"pmid":"21637913","id":"PMC_21637913","title":"Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21637913","citation_count":39,"is_preprint":false},{"pmid":"27008282","id":"PMC_27008282","title":"CCL25/CCR9 Signal Promotes Migration and Invasion in Hepatocellular and Breast Cancer Cell Lines.","date":"2016","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27008282","citation_count":36,"is_preprint":false},{"pmid":"28380463","id":"PMC_28380463","title":"Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28380463","citation_count":33,"is_preprint":false},{"pmid":"11997671","id":"PMC_11997671","title":"Role of the CC chemokine receptor 9/TECK interaction in apoptosis.","date":"2002","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/11997671","citation_count":31,"is_preprint":false},{"pmid":"30375700","id":"PMC_30375700","title":"CD33+ CD14+ CD11b+ HLA-DR- monocytic myeloid-derived suppressor cells recruited and activated by CCR9/CCL25 are crucial for the pathogenic progression of endometriosis.","date":"2018","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/30375700","citation_count":30,"is_preprint":false},{"pmid":"23151454","id":"PMC_23151454","title":"Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.","date":"2012","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23151454","citation_count":29,"is_preprint":false},{"pmid":"27003360","id":"PMC_27003360","title":"Rainbow trout CK9, a CCL25-like ancient chemokine that attracts and regulates B cells and macrophages, the main antigen presenting cells in fish.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27003360","citation_count":29,"is_preprint":false},{"pmid":"22842207","id":"PMC_22842207","title":"Cloning, expression and characterization of CCL21 and CCL25 chemokines in zebrafish.","date":"2012","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22842207","citation_count":29,"is_preprint":false},{"pmid":"22539297","id":"PMC_22539297","title":"CCL25 induces α₄β₇ integrin-dependent migration of IL-17⁺ γδ T lymphocytes during an allergic reaction.","date":"2012","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22539297","citation_count":29,"is_preprint":false},{"pmid":"20081876","id":"PMC_20081876","title":"Abnormal regulation of chemokine TECK and its receptor CCR9 in the endometriotic milieu is involved in pathogenesis of endometriosis by way of enhancing invasiveness of endometrial stromal cells.","date":"2010","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20081876","citation_count":27,"is_preprint":false},{"pmid":"17510295","id":"PMC_17510295","title":"Intracellular signaling required for CCL25-stimulated T cell adhesion mediated by the integrin alpha4beta1.","date":"2007","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/17510295","citation_count":27,"is_preprint":false},{"pmid":"20036004","id":"PMC_20036004","title":"Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9.","date":"2009","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/20036004","citation_count":27,"is_preprint":false},{"pmid":"23958031","id":"PMC_23958031","title":"Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum.","date":"2013","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23958031","citation_count":26,"is_preprint":false},{"pmid":"17250588","id":"PMC_17250588","title":"Expression of mucosal chemokines TECK/CCL25 and MEC/CCL28 during fetal development of the ovine mucosal immune system.","date":"2007","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17250588","citation_count":23,"is_preprint":false},{"pmid":"30863398","id":"PMC_30863398","title":"A Subset of CCL25-Induced Gut-Homing T Cells Affects Intestinal Immunity to Infection and Cancer.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30863398","citation_count":22,"is_preprint":false},{"pmid":"31065973","id":"PMC_31065973","title":"Toll-Like Receptor 4 Promotes Th17 Lymphocyte Infiltration Via CCL25/CCR9 in Pathogenesis of Experimental Autoimmune Encephalomyelitis.","date":"2019","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31065973","citation_count":22,"is_preprint":false},{"pmid":"33347617","id":"PMC_33347617","title":"CCL25 and CCR9 is a unique pathway that potentiates pannus formation by remodeling RA macrophages into mature osteoclasts.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33347617","citation_count":21,"is_preprint":false},{"pmid":"15833102","id":"PMC_15833102","title":"Transient expression of CC chemokine TECK in the ovary during ovulation: its potential role in ovulation.","date":"2005","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/15833102","citation_count":21,"is_preprint":false},{"pmid":"31733111","id":"PMC_31733111","title":"Decreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren's syndrome to facilitate their concerted migration.","date":"2019","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31733111","citation_count":20,"is_preprint":false},{"pmid":"33023277","id":"PMC_33023277","title":"Parenterally Administered Porcine Epidemic Diarrhea Virus-Like Particle-Based Vaccine Formulated with CCL25/28 Chemokines Induces Systemic and Mucosal Immune Protectivity in Pigs.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/33023277","citation_count":20,"is_preprint":false},{"pmid":"24874458","id":"PMC_24874458","title":"CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis.","date":"2014","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24874458","citation_count":19,"is_preprint":false},{"pmid":"33058852","id":"PMC_33058852","title":"The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes.","date":"2020","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/33058852","citation_count":18,"is_preprint":false},{"pmid":"32135342","id":"PMC_32135342","title":"A CCL25 chemokine functions as a chemoattractant and an immunomodulator in black rockfish, Sebastes schlegelii.","date":"2020","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32135342","citation_count":18,"is_preprint":false},{"pmid":"32346420","id":"PMC_32346420","title":"CCL25 promotes the migration and invasion of non-small cell lung cancer cells by regulating VEGF and MMPs in a CCR9-dependent manner.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32346420","citation_count":18,"is_preprint":false},{"pmid":"20855113","id":"PMC_20855113","title":"Role of Rho-ROCK signaling in MOLT4 cells metastasis induced by CCL25.","date":"2010","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/20855113","citation_count":16,"is_preprint":false},{"pmid":"34808497","id":"PMC_34808497","title":"LINC00853 restrains T cell acute lymphoblastic leukemia invasion and infiltration by regulating CCR9/CCL25.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34808497","citation_count":15,"is_preprint":false},{"pmid":"30060561","id":"PMC_30060561","title":"Chemokine CCL25 Induces Migration and Extracellular Matrix Production of Anulus Fibrosus-Derived Cells.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30060561","citation_count":14,"is_preprint":false},{"pmid":"24936795","id":"PMC_24936795","title":"CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24936795","citation_count":14,"is_preprint":false},{"pmid":"35782530","id":"PMC_35782530","title":"CCL25 Inhibition Alleviates Sepsis-Induced Acute Lung Injury and Inflammation.","date":"2022","source":"Infection and drug resistance","url":"https://pubmed.ncbi.nlm.nih.gov/35782530","citation_count":13,"is_preprint":false},{"pmid":"33310185","id":"PMC_33310185","title":"Impaired CCR9/CCL25 signalling induced by inefficient dendritic cells contributes to intestinal immune imbalance in nonalcoholic steatohepatitis.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33310185","citation_count":13,"is_preprint":false},{"pmid":"19187430","id":"PMC_19187430","title":"Association between decreased CXCL12 and CCL25 expression and increased apoptosis in lymphoid tissues of cynomolgus macaques during SIV infection.","date":"2008","source":"Journal of medical primatology","url":"https://pubmed.ncbi.nlm.nih.gov/19187430","citation_count":12,"is_preprint":false},{"pmid":"23456208","id":"PMC_23456208","title":"Anti-CCL25 antibody prolongs skin allograft survival by blocking CCR9 expression and impairing splenic T-cell function.","date":"2013","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/23456208","citation_count":12,"is_preprint":false},{"pmid":"36161509","id":"PMC_36161509","title":"ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/36161509","citation_count":11,"is_preprint":false},{"pmid":"20688401","id":"PMC_20688401","title":"Partial characterization and distribution of the chemokines CCL25 and CCL28 in the bovine system.","date":"2010","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20688401","citation_count":11,"is_preprint":false},{"pmid":"37854863","id":"PMC_37854863","title":"PCSK9 promotes tumor cell proliferation and migration by facilitating CCL25 secretion in esophageal squamous cell carcinoma.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/37854863","citation_count":11,"is_preprint":false},{"pmid":"30583576","id":"PMC_30583576","title":"Dose-Dependent Effect of Mesenchymal Stromal Cell Recruiting Chemokine CCL25 on Porcine Tissue-Engineered Healthy and Osteoarthritic Cartilage.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30583576","citation_count":10,"is_preprint":false},{"pmid":"29408710","id":"PMC_29408710","title":"Delayed release of chemokine CCL25 with bioresorbable microparticles for mobilization of human mesenchymal stem cells.","date":"2018","source":"Acta biomaterialia","url":"https://pubmed.ncbi.nlm.nih.gov/29408710","citation_count":10,"is_preprint":false},{"pmid":"28624470","id":"PMC_28624470","title":"Molecular cloning and expression analysis of CCL25 and its receptor CCR9s from Epinephelus coioides post Cryptocaryon irritans infection.","date":"2017","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28624470","citation_count":10,"is_preprint":false},{"pmid":"33766057","id":"PMC_33766057","title":"Therapies with CCL25 require controlled release via microparticles to avoid strong inflammatory reactions.","date":"2021","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/33766057","citation_count":8,"is_preprint":false},{"pmid":"30977553","id":"PMC_30977553","title":"CCL25-Supplemented Hyaluronic Acid Attenuates Cartilage Degeneration in a Guinea Pig Model of Knee Osteoarthritis.","date":"2019","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/30977553","citation_count":8,"is_preprint":false},{"pmid":"39236454","id":"PMC_39236454","title":"Piezo1 activation on microglial cells exacerbates demyelination in sepsis by influencing the CCL25/GRP78 pathway.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39236454","citation_count":7,"is_preprint":false},{"pmid":"37126939","id":"PMC_37126939","title":"CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37126939","citation_count":7,"is_preprint":false},{"pmid":"18592157","id":"PMC_18592157","title":"Decreased expression of intestinal chemokine TECK/CCL25 in experimental obstructive jaundice and its reversal following internal biliary drainage.","date":"2008","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18592157","citation_count":7,"is_preprint":false},{"pmid":"30284497","id":"PMC_30284497","title":"CCL25 chemokine-guided stem cell attraction: an assessment of possible benefits and risks.","date":"2018","source":"Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30284497","citation_count":6,"is_preprint":false},{"pmid":"36003306","id":"PMC_36003306","title":"CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma via the PI3K/AKT signaling pathway.","date":"2022","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/36003306","citation_count":6,"is_preprint":false},{"pmid":"35185906","id":"PMC_35185906","title":"Antigen-Presenting Cells and T Cells Interact in a Specific Area of the Intestinal Mucosa Defined by the Ccl25-Ccr9 Axis in Medaka.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35185906","citation_count":6,"is_preprint":false},{"pmid":"34286444","id":"PMC_34286444","title":"CCL25 Signaling in the Tumor Microenvironment.","date":"2021","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/34286444","citation_count":6,"is_preprint":false},{"pmid":"19249122","id":"PMC_19249122","title":"Importance of CCL25 in the attraction of T cells and the role of IL-7 on the signaling pathways in intestinal epithelial cells.","date":"2008","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19249122","citation_count":5,"is_preprint":false},{"pmid":"34901814","id":"PMC_34901814","title":"Dissecting the contribution of single nucleotide polymorphisms in CCR9 and CCL25 genomic regions to the celiac disease phenotype.","date":"2021","source":"Journal of translational autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/34901814","citation_count":5,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52279,"output_tokens":8222,"usd":0.140083},"stage2":{"model":"claude-opus-4-6","input_tokens":12228,"output_tokens":4997,"usd":0.279097},"total_usd":0.41918,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CCL25 (TECK) is produced by thymic dendritic cells and exhibits chemotactic activity for activated macrophages, dendritic cells, and thymocytes in vitro.\",\n      \"method\": \"Recombinant protein chemotaxis assay; source identification by cell-type-specific expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original discovery paper with in vitro chemotaxis assay and cellular source identification, foundational and highly cited\",\n      \"pmids\": [\"9285413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCL25 binds specifically to the orphan receptor GPR-9-6 (renamed CCR9), inducing intracellular calcium mobilization and in vitro migration of CCR9-transfected cells; no other chemokines tested produced responses via CCR9.\",\n      \"method\": \"Calcium flux assay and chemotaxis assay in CCR9-transfected HEK293 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in transfected cells with receptor deorphanization; replicated across multiple labs\",\n      \"pmids\": [\"10229797\", \"10498628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCL25 (TECK) efficaciously induces chemotaxis of immature CD4+CD8+ double-positive and mature CD4+ and CD8+ single-positive human thymocytes via CCR9.\",\n      \"method\": \"In vitro chemotaxis assay with primary human thymocytes and CCR9-expressing cell lines\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct chemotaxis assay with primary cells; independently replicated\",\n      \"pmids\": [\"10498628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL25 is produced predominantly by thymic epithelial cells (not dendritic cells) and by small intestinal epithelial cells; it chemoattracts both double-positive and single-positive thymocytes via CCR9.\",\n      \"method\": \"Immunohistochemistry and in vitro migration assays; CCR9 cDNA cloning and localization\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type source reassignment with IHC and functional migration assays, highly cited\",\n      \"pmids\": [\"10602049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR9 is expressed at high levels on essentially all small intestinal CD4+ and CD8+ T lymphocytes, and CCL25 is expressed selectively by small intestinal crypt epithelium; this CCL25–CCR9 axis mediates selective migration of lymphocytes to the small intestinal mucosa.\",\n      \"method\": \"Immunohistochemistry; in vitro migration assay; flow cytometry of tissue lymphocytes\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, highly cited, foundational tissue-localization paper\",\n      \"pmids\": [\"10974041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL25 also binds with high affinity to CCX-CKR (provisionally CCR10), a second chemokine receptor, with IC50 <15 nM, as determined by stalkokine adhesion and radiolabeled ligand competition assays.\",\n      \"method\": \"Stalkokine adhesion assay; radiolabeled ligand binding and competition with >80 chemokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro binding assay with >80 chemokines tested; single lab but rigorous methodology\",\n      \"pmids\": [\"10706668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR9 exists as two alternatively spliced isoforms, CCR9A (12 extra N-terminal amino acids) and CCR9B; CCR9A has a lower EC50 for CCL25 and is desensitized at doses that do not silence CCR9B, extending the concentration range over which cells respond to CCL25.\",\n      \"method\": \"cDNA cloning, calcium flux assay and chemotaxis assay comparing CCR9A vs CCR9B transfectants\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in transfected cells with functional dose-response comparison of two isoforms\",\n      \"pmids\": [\"10640743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR9 engagement by CCL25 activates PI3K-dependent phosphorylation of Akt, GSK-3β, and FKHR, and MAPK; PI3K (but not MAPK) is required for CCR9-mediated chemotaxis. CCL25/CCR9 signaling provides a cell survival signal blocking cycloheximide-induced and partially Fas-mediated apoptosis independently of c-FLIPL.\",\n      \"method\": \"Chemical inhibitor studies, immunoblotting for phosphorylated proteins, apoptosis assays (PARP cleavage, caspase-3 activation) in MOLT4 cells naturally expressing CCR9\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple signaling pathway dissections with chemical inhibitors and functional readouts in endogenous-receptor-expressing cells\",\n      \"pmids\": [\"11493434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL25 selectively chemoattracts IgA antibody-secreting cells (ASC) from spleen, Peyer's patches, and mesenteric lymph nodes via CCR9; IgG- and IgM-ASC respond poorly. Small intestinal epithelial cells selectively express CCL25, consistent with targeting IgA-producing cells to the gut wall.\",\n      \"method\": \"In vitro migration/chemotaxis assays with sorted antibody-secreting cells; immunohistochemistry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct chemotaxis assay with multiple ASC populations and controls; highly cited\",\n      \"pmids\": [\"11805153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCR9 expression is maintained on CD8αβ+ T cells activated in mesenteric lymph nodes but rapidly downregulated on those activated in peripheral lymph nodes; in vivo neutralization of CCL25 reduced the ability of CCR9+ CD8αβ+ lymphocytes to populate the small-intestinal epithelium.\",\n      \"method\": \"TCR transgenic T cell transfer model; in vivo antibody neutralization; flow cytometry\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization plus adoptive transfer with defined cellular readout, highly cited\",\n      \"pmids\": [\"12393847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL25–CCR9 signaling is essential for cryptopatch (CP) formation in the gut and the consequent thymus-independent generation of intestinal intraepithelial T lymphocytes (IEL); CD11c+ dendritic stromal cells in CPs express CCL25, and c-kit+ Lin− bone marrow progenitors express CCR9 and migrate in response to CCL25.\",\n      \"method\": \"CCL25 intrakine transgenic mice (dominant-negative CCL25 signaling); bone marrow reconstitution; RT-PCR; chemotaxis assay\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (intrakine) with specific anatomical and cellular phenotype, plus functional chemotaxis assay\",\n      \"pmids\": [\"12096027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Anti-CCL25 antibody administration to neonatal mice reduces CD8αα+TCRγδ+ and CD8αα+TCRαβ+ IEL by ~50%, demonstrating CCL25 is required for maintenance/development of IEL precursors in the small intestine.\",\n      \"method\": \"In vivo antibody neutralization in neonatal mice; flow cytometry; CCR9 expression analysis on IEL precursors\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization with specific quantitative cellular phenotype\",\n      \"pmids\": [\"12442331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCR9 is expressed on the majority of CD4+CD8+ double-positive thymocytes but not on CD4−CD8− double-negative thymocytes; CD69+ thymocytes show enhanced CCL25-induced migration compared to CD69− thymocytes; TCR stimulation augments CCL25 responsiveness; ~50% of γδTCR+ thymocytes and peripheral γδ T cells express CCR9 and migrate in response to CCL25.\",\n      \"method\": \"Polyclonal anti-CCR9 antibody generation; flow cytometry; in vitro migration assays of sorted thymocyte subpopulations\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic characterization with validated antibody, multiple cell populations, and functional assays\",\n      \"pmids\": [\"11751956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCL25/CCR9-mediated lymphocyte adhesion to small intestinal microvessels is demonstrated in vivo; CCR9 desensitization or anti-CCL25 antibody significantly inhibits LPL adhesion in small (but not large) intestine, including TNF-α-induced adhesion; TNF-α upregulates CCL25 expression in small intestinal lamina propria.\",\n      \"method\": \"Intravital microscopy; in vivo CCR9 desensitization with CCL25; anti-CCL25 antibody neutralization\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo intravital imaging with specific perturbations; functional consequence demonstrated\",\n      \"pmids\": [\"14592943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL25 is aberrantly expressed on hepatic endothelium in primary sclerosing cholangitis (PSC) and activates α4β7 binding to MAdCAM-1 on hepatic endothelium, thereby recruiting gut-primed CCR9+ T cells to the liver and mediating extra-intestinal inflammation.\",\n      \"method\": \"Immunohistochemistry; flow cytometry; in vitro adhesion assay under flow conditions\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined with multiple methods; highly cited; first demonstration in humans of ectopic CCL25-driven lymphocyte homing\",\n      \"pmids\": [\"15557349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCR9/CCL25 signaling promotes induction and function of CD103 on CD8+ intestinal IEL: CCR9-deficient CD8+ T cells show delayed CD103 induction after entry into small intestinal epithelium; CCL25 induces transient, dose-dependent, pertussis toxin-sensitive CD103-mediated adhesion of CD8+ IEL to E-cadherin.\",\n      \"method\": \"CCR9−/− mice; adoptive transfer; pertussis toxin treatment; adhesion assay to mEFc fusion protein\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific phenotype plus functional adhesion assay with pertussis toxin dissection\",\n      \"pmids\": [\"15368288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL25 expression in small intestinal epithelial cells is regulated by caudal-related homeobox (Cdx) transcription factors: Cdx proteins bind to putative Cdx sites in the CCL25 promoter (EMSA), and co-transfection of Cdx-1 or Cdx-2 significantly increases CCL25 promoter activity and endogenous CCL25 mRNA in intestinal cell lines.\",\n      \"method\": \"Promoter deletion analysis; EMSA; co-transfection/reporter assay; RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — EMSA demonstrating direct protein-DNA binding plus functional reporter assay with cotransfection\",\n      \"pmids\": [\"16517733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL25 and CCL28 redundantly recruit IgA+ plasmablasts to the small intestinal lamina propria after rotavirus infection; combined antibody blockade of both chemokines (but neither alone) prevents IgA+ plasmablast accumulation; CCR9 and α4β7 are coexpressed on IgA+ plasmablasts and both pathways are required.\",\n      \"method\": \"CCR9 knockout mice; in vivo antibody neutralization (anti-CCL25, anti-CCL28, anti-α4); flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO combined with in vivo neutralization; demonstrates redundancy and pathway cooperation\",\n      \"pmids\": [\"16670280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCL25 is required for antigen-dependent accumulation of CCR9high memory-phenotype CD8+ T cells within the small intestinal lamina propria and epithelium, but is dispensable for generating CCR9high memory phenotype in mesenteric lymph nodes.\",\n      \"method\": \"CCL25−/− mice; TCR-transgenic naive CD8+ T cell transfer; oral antigen sensitization; flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CCL25 KO mice generated and used in adoptive transfer model with clear dissociation of priming vs. trafficking roles\",\n      \"pmids\": [\"17548595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCL25-stimulated α4β1-integrin-mediated adhesion of thymocytes to CS-1/fibronectin and VCAM-1 requires activation of Rac and Rap1 GTPases; downstream effectors WAVE2 and RAPL (but not RIAM) are required for efficient CCL25-triggered integrin-dependent adhesion; Rac-WAVE2 drives post-adhesion actin-dependent spreading.\",\n      \"method\": \"GTPase activity assays; shRNA knockdown of WAVE2, RAPL, RIAM; adhesion assays on CS-1/FN and VCAM-1; Molt-4 CCR9+/α4β1+ cell line\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic pathway dissection with multiple shRNA knockdowns and functional adhesion readouts\",\n      \"pmids\": [\"17510295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL25 and CCL28 both trigger α4β7-dependent lymphocyte arrest on immobilized MAdCAM-1 under shear flow conditions, but have no effect on α4β1/VCAM-1-mediated adhesion, demonstrating selective activation of α4β7 integrin.\",\n      \"method\": \"Flow-based adhesion assay with immobilized chemokines on MAdCAM-1 and VCAM-1; integrin-blocking antibodies\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution under physiological shear with selective integrin pathway dissection\",\n      \"pmids\": [\"18308860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Androgen withdrawal increases thymic epithelial cell (TEC) production of CCL25, particularly by UEA+ TEC; blockade of CCL25 abrogates the effects of castration by impairing early thymic progenitor (ETP) entry, retarding thymocyte development, and limiting thymic size increase.\",\n      \"method\": \"Castration model; CCL25 antibody blockade; adoptive transfer of quantified precursors; flow cytometry of ETP and TEC populations\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo blockade with specific mechanistic cellular phenotypes; defines CCL25 as downstream effector of androgen signaling in thymus\",\n      \"pmids\": [\"18694999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCR9-CCL25 interactions promote migration and invasion of cutaneous melanoma cells expressing CCR9 toward CCL25 gradients in a CCR9-dependent manner (blocked by anti-CCR9 antibody or CCR9 siRNA); CCR9+ melanoma cells also express α4β1 integrin, suggesting cooperative adhesion mechanisms.\",\n      \"method\": \"In vitro migration and invasion assays; anti-CCR9 antibody and siRNA knockdown; flow cytometry; RT-PCR\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor knockdown with two orthogonal methods (antibody and siRNA) with functional migration readouts\",\n      \"pmids\": [\"18245522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"P-selectin and CCL25 are periodically co-expressed in the thymus and both are essential components of the thymic gate-keeping mechanism for T-cell progenitor (TCP) importation; sphingosine-1-phosphate (S1P) from peripheral lymphocytes feeds back to regulate thymic P-selectin expression and TCP receptivity.\",\n      \"method\": \"Periodic expression analysis; P-selectin ligand mutant mice; competitive TCP reconstitution; S1P manipulation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic models plus functional reconstitution experiments defining CCL25 role in thymic gating\",\n      \"pmids\": [\"19289576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Ezrin is a key molecule in CCL25-induced MOLT4 cell polarization and invasive behavior: CCL25 induces pseudopodium formation and ERM translocation from cytoplasm to cell membrane; ezrin silencing by miRNA impairs CCL25-induced cell polarization and invasion.\",\n      \"method\": \"miRNA-mediated ezrin silencing; confocal microscopy of ERM translocation; invasion assay\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gene knockdown with functional readout; single lab\",\n      \"pmids\": [\"20036004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCR9-CCL25 signaling activates PI3K/Akt and ERK1/2 pathways in prostate cancer cells to upregulate antiapoptotic proteins (PI3K, AKT, ERK1/2, GSK-3β) and suppress caspase-3 activation; PI3K inhibitor wortmannin abrogates these effects; in vivo tumor burden is reduced by CCL25 neutralizing antibodies combined with etoposide.\",\n      \"method\": \"PI3K inhibitor (wortmannin); anti-CCR9 monoclonal antibodies; caspase-3 assay; in vivo mouse xenograft\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro pathway inhibition plus in vivo xenograft; single lab\",\n      \"pmids\": [\"20127861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL25 induces RhoA activation and MLC phosphorylation (RhoA-ROCK-MLC axis) in MOLT4 cells; C3 exoenzyme and ROCK inhibitor Y-27632 block CCL25-induced cell migration and chemotaxis.\",\n      \"method\": \"GTPase activity assay; pharmacological inhibitors (C3 exoenzyme, Y-27632); migration and chemotaxis assay\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway inhibition with multiple agents and functional readouts; single lab\",\n      \"pmids\": [\"20855113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL25 stimulates migration of human subchondral mesenchymal progenitor cells in a CCR9-dependent fashion, as demonstrated by chemotaxis assay; these progenitors express CCR9 mRNA and protein.\",\n      \"method\": \"96-well chemotaxis assay; gene expression analysis (real-time PCR); immunohistochemistry for CCR9\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional chemotaxis assay with receptor expression validation; single lab\",\n      \"pmids\": [\"20709179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL25 promotes breast cancer cell (MDA-MB-231) migration and invasion through CCR9; neutralizing CCR9-CCL25 interactions impairs migration and invasion; CCL25 enhances expression of active MMP-1, -9, -11, and -13 in a CCR9-dependent fashion.\",\n      \"method\": \"Migration and invasion assays; anti-CCR9 neutralization; ELISA for active MMP proteins\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor neutralization with functional readouts and downstream MMP measurement; single lab\",\n      \"pmids\": [\"21344163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL25/CCR9 interactions regulate colitis in the large intestine: CCR9−/− mice are more susceptible to DSS colitis, with accumulation of activated macrophages, elevated Th1/Th17 cytokines, and altered DC subset balance in mesenteric lymph nodes during recovery.\",\n      \"method\": \"CCR9−/− mice; DSS colitis model; flow cytometry; cytokine quantification (mRNA and protein); IBD scoring\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple mechanistic readouts demonstrating CCL25/CCR9 role in DC subset balance and cytokine regulation\",\n      \"pmids\": [\"21283540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Multiple myeloma cells produce CCL25 as a major chemoattractant for bone marrow mesenchymal stromal cells (MSCs); CCL25-recruited MSCs favor myeloma cell proliferation and protect against apoptosis by enhancing AKT and ERK activity and upregulating CyclinD2, CDK4, and Bcl-XL.\",\n      \"method\": \"In vitro and in vivo migration assays; CCL25 neutralization; co-culture proliferation/apoptosis assays; western blotting; intrafemoral coengraftment\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CCL25 identified as chemoattractant by neutralization, pathway activation characterized, and in vivo validation\",\n      \"pmids\": [\"22102554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL25-induced drug resistance in T-ALL MOLT4 cells involves phosphorylated ERM (p-ERM) serving as a scaffold linking P-glycoprotein (P-gp) to F-actin; ERM silencing by shRNA releases P-gp from F-actin and restores drug sensitivity.\",\n      \"method\": \"shRNA-mediated ERM knockdown; co-immunoprecipitation of p-ERM, P-gp, and F-actin; P-gp functional assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus shRNA knockdown with functional drug-resistance readout; mechanistic scaffolding role defined\",\n      \"pmids\": [\"23326330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL25-stimulated endometrial stromal cell-derived Treg differentiation is mediated via AKT/STAT3 signaling; ESC/macrophage-derived TECK induces Treg differentiation, increases IL-10, TGF-β, and CD73 expression, and represses Treg apoptosis (reducing Fas/FasL); anti-TECK neutralizing antibodies inhibit these effects.\",\n      \"method\": \"Co-culture experiments; AKT/STAT3 signaling analysis; anti-TECK neutralizing antibodies; in vitro and in vivo trials\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway identified with neutralizing antibody validation and in vivo confirmation; single lab\",\n      \"pmids\": [\"25275597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL25 induces Wnt5a expression in MOLT4 T-ALL cells via promotion of PKC expression and activation; Wnt5a then promotes cell migration, invasion, actin polarization, and lamellipodia/filopodia formation via PI3K/Akt-RhoA pathway; PI3K/Akt or RhoA knockdown/inhibition rescues these effects.\",\n      \"method\": \"Transwell invasion/migration assays; western blotting; siRNA and inhibitor knockdown of PI3K/Akt and RhoA; confocal and scanning electron microscopy; mouse xenograft\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with multiple inhibitors/knockdowns and in vivo validation; single lab\",\n      \"pmids\": [\"28380463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL25 acts via the Gαi-coupled receptor CCR9 to inhibit glucose-induced insulin secretion in a concentration-dependent manner, enhance cytokine-induced apoptosis, and reduce cAMP levels in human and mouse islets; these effects are blocked by the CCR9 antagonist vercirnon.\",\n      \"method\": \"Insulin secretion assay; cAMP accumulation assay; apoptosis assay in primary human and mouse islets; CCR9 antagonist (vercirnon)\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro assays on primary human and mouse islets with pharmacological antagonist validation; multiple functional readouts\",\n      \"pmids\": [\"33058852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL25 stimulates RA FLS and monocyte migration via p38 and ERK phosphorylation; CCL25 polarizes RA monocytes into non-traditional M1 macrophages producing IL-8 and CCL2 via p38 and ERK cascades; CCL25-induced osteoclastogenesis is regulated by RANK, cathepsin K, and TNF-α but not RANKL.\",\n      \"method\": \"p38 and ERK inhibitors; flow cytometry; cytokine ELISA; osteoclast differentiation assay in RA synovial tissue/cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway defined with kinase inhibitors and functional differentiation assays; single lab\",\n      \"pmids\": [\"33347617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CCL25 promotes increased endothelial permeability by reducing tight junction protein expression via activation of the P38 MAPK pathway; NF-κB inhibition in HPMECs decreases CCL25 expression; recombinant CCL25 increases cell permeability and inflammatory cytokine expression.\",\n      \"method\": \"LPS-stimulated HPMECs; TEER measurement; FITC-fluorescence intensity; luciferase assays; chromatin immunoprecipitation; P38 MAPK pathway analysis\",\n      \"journal\": \"Infection and drug resistance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP and luciferase assays for NF-κB regulation plus functional permeability assays; single lab\",\n      \"pmids\": [\"35782530\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL25 is a CC chemokine produced constitutively by thymic epithelial cells and small intestinal crypt epithelium (regulated by Cdx transcription factors and NF-κB) that acts as the exclusive ligand for CCR9 (a Gαi-coupled GPCR existing as alternatively spliced CCR9A/B isoforms with different ligand sensitivities), activating PI3K/Akt, p38/ERK MAPK, and Rac/Rap1-GTPase signaling to drive chemotaxis, α4β7- and α4β1-integrin-dependent adhesion to MAdCAM-1/VCAM-1, cell survival, osteoclastogenesis, and cancer cell invasion, while its tissue-restricted expression pattern makes it the master organizer of lymphocyte homing to the small intestine and thymus.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCL25 (TECK) is a CC chemokine that functions as the principal ligand for CCR9 to orchestrate lymphocyte trafficking to the thymus and small intestine, governing T-cell development, intestinal intraepithelial lymphocyte maintenance, and IgA-producing cell recruitment. Constitutively produced by thymic epithelial cells and small intestinal crypt epithelium under transcriptional control of Cdx homeodomain proteins and NF-κB, CCL25 binds CCR9 (a Gαi-coupled receptor with two alternatively spliced isoforms that extend the ligand concentration–response range) and also binds the atypical receptor CCX-CKR [PMID:10602049, PMID:10974041, PMID:16517733, PMID:10706668, PMID:10640743, PMID:35782530]. Engagement of CCR9 activates PI3K/Akt, p38/ERK MAPK, and Rac/Rap1 GTPase cascades that drive chemotaxis, α4β7-integrin–dependent arrest on MAdCAM-1 under shear flow, α4β1-mediated adhesion to VCAM-1/fibronectin, anti-apoptotic signaling, and CD103-dependent epithelial retention of intraepithelial lymphocytes [PMID:11493434, PMID:17510295, PMID:18308860, PMID:15368288, PMID:20855113]. Beyond immune homeostasis, CCL25–CCR9 signaling promotes cancer cell migration and invasion through MMP upregulation and Wnt5a/RhoA pathways, drives osteoclastogenesis via p38/ERK independently of RANKL, and inhibits glucose-stimulated insulin secretion by reducing cAMP in pancreatic islets [PMID:18245522, PMID:21344163, PMID:28380463, PMID:33347617, PMID:33058852].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"The discovery of TECK (CCL25) as a thymus-expressed chemokine with chemotactic activity for macrophages, dendritic cells, and thymocytes established the existence of a tissue-restricted chemokine potentially governing thymic cell trafficking.\",\n      \"evidence\": \"Recombinant protein chemotaxis assay with primary immune cell populations\",\n      \"pmids\": [\"9285413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cognate receptor unknown\", \"In vivo role undemonstrated\", \"Molecular mechanism of chemotaxis undetermined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of GPR-9-6 (CCR9) as the specific receptor for CCL25 resolved the signaling entry point, showing exclusive ligand–receptor pairing with calcium mobilization and chemotaxis, and defined CCL25 as active on both immature double-positive and mature single-positive thymocytes.\",\n      \"evidence\": \"Receptor deorphanization via calcium flux and chemotaxis in CCR9-transfected HEK293 cells; primary human thymocyte migration assays\",\n      \"pmids\": [\"10229797\", \"10498628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement not demonstrated\", \"Downstream signaling cascade uncharacterized\", \"Additional receptor interactions unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping CCL25 production to thymic epithelial cells and small intestinal crypt epithelium, combined with finding high CCR9 expression on all small intestinal T cells, established the CCL25–CCR9 axis as a dual tissue-homing system for thymus and gut; discovery of CCR9A/B splice variants and CCX-CKR binding expanded the receptor biology.\",\n      \"evidence\": \"Immunohistochemistry, flow cytometry of tissue lymphocytes, cDNA cloning with dose-response comparison of CCR9 isoforms, radiolabeled ligand binding to CCX-CKR\",\n      \"pmids\": [\"10602049\", \"10974041\", \"10640743\", \"10706668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo genetic loss-of-function evidence lacking\", \"Functional significance of CCX-CKR binding unclear\", \"Transcriptional regulation of CCL25 expression unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Dissection of intracellular signaling revealed that CCL25–CCR9 activates PI3K/Akt (required for chemotaxis) and MAPK pathways, and provides anti-apoptotic survival signals blocking cycloheximide- and partially Fas-mediated cell death, establishing CCL25 as both a migratory and survival factor.\",\n      \"evidence\": \"Chemical inhibitor studies, phospho-protein immunoblotting, and apoptosis assays (PARP cleavage, caspase-3) in endogenous CCR9-expressing MOLT4 cells\",\n      \"pmids\": [\"11493434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GTPase-level effectors for adhesion not identified\", \"Survival mechanism in primary cells not confirmed\", \"Relative contribution of PI3K vs MAPK to different outcomes unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"In vivo studies using antibody neutralization, CCL25-intrakine transgenic mice, and CCR9 expression profiling demonstrated that CCL25 is required for IgA-ASC recruitment to the gut, IEL maintenance and development, cryptopatch formation, and CD8+ T cell homing to the small intestinal epithelium.\",\n      \"evidence\": \"In vivo anti-CCL25 antibody neutralization in neonatal and adult mice; CCL25-intrakine transgenic model; TCR-transgenic adoptive transfer; sorted ASC chemotaxis assays\",\n      \"pmids\": [\"11805153\", \"12393847\", \"12096027\", \"12442331\", \"11751956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCL25 complete knockout mouse phenotype not yet reported at this point\", \"Redundancy with other gut-homing chemokines not fully delineated\", \"Role in thymic progenitor entry not directly tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"CCL25 was shown to activate α4β7 integrin binding to MAdCAM-1 on hepatic endothelium in primary sclerosing cholangitis, establishing the first ectopic CCL25 disease mechanism, and to promote CD103-mediated IEL adhesion to E-cadherin in a pertussis toxin-sensitive manner, defining an additional integrin-activation pathway.\",\n      \"evidence\": \"Flow-based adhesion assay on human hepatic endothelium; CCR9−/− adoptive transfer; pertussis toxin treatment with adhesion readout\",\n      \"pmids\": [\"15557349\", \"15368288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ectopic CCL25 expression occurs in other inflammatory liver diseases unclear\", \"Signaling intermediates linking CCR9 to CD103 activation not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Transcriptional control of CCL25 was established by showing that Cdx-1 and Cdx-2 homeodomain proteins directly bind the CCL25 promoter to drive its intestinal expression, and functional redundancy with CCL28 was demonstrated for IgA plasmablast recruitment after rotavirus infection.\",\n      \"evidence\": \"EMSA, promoter-reporter assays, cotransfection in intestinal cell lines; CCR9-KO mice and combined anti-CCL25/anti-CCL28 antibody blockade\",\n      \"pmids\": [\"16517733\", \"16670280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Factors governing thymic CCL25 transcription not identified\", \"Whether Cdx regulation is direct in vivo (ChIP-seq) not shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The GTPase effector pathway downstream of CCR9 was mapped: CCL25 activates Rac and Rap1 to drive α4β1-integrin adhesion to VCAM-1/fibronectin via WAVE2 and RAPL effectors respectively, and CCL25-KO mice showed that CCL25 is required for gut accumulation but not priming of CCR9-high memory CD8+ T cells.\",\n      \"evidence\": \"shRNA knockdown of WAVE2/RAPL/RIAM with adhesion assays; CCL25−/− mice with oral antigen sensitization and adoptive transfer\",\n      \"pmids\": [\"17510295\", \"17548595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Rac-WAVE2 and Rap1-RAPL pathways are simultaneously or sequentially engaged unknown\", \"Role of CCL25 in memory T cell survival in situ not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"CCL25 was identified as the effector linking androgen withdrawal to enhanced thymic progenitor entry, and was shown to selectively trigger α4β7-dependent (but not α4β1-dependent) lymphocyte arrest under shear flow, while CCR9–CCL25 signaling was found to drive melanoma cell migration and invasion.\",\n      \"evidence\": \"Castration model with CCL25 antibody blockade and ETP quantification; flow-based adhesion reconstitution with MAdCAM-1/VCAM-1; anti-CCR9 antibody and siRNA in melanoma invasion assays\",\n      \"pmids\": [\"18694999\", \"18308860\", \"18245522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selectivity for α4β7 over α4β1 under flow not defined\", \"In vivo melanoma metastasis not tested with CCL25 perturbation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"CCL25 was integrated into a periodic thymic gating model where its co-expression with P-selectin controls cyclical T-cell progenitor importation, and ezrin was identified as a cytoskeletal scaffold mediating CCL25-induced cell polarization and invasion.\",\n      \"evidence\": \"Periodic expression analysis with genetic models and competitive TCP reconstitution; miRNA-mediated ezrin silencing with confocal microscopy and invasion assay\",\n      \"pmids\": [\"19289576\", \"20036004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking S1P feedback to CCL25 periodicity not established\", \"ERM role confirmed only in MOLT4 cells, not primary lymphocytes\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Cancer biology studies extended CCL25–CCR9 survival signaling to prostate cancer (PI3K/Akt/ERK-dependent anti-apoptosis reversed by wortmannin and anti-CCL25 antibodies in xenografts), and the RhoA-ROCK-MLC axis was identified as required for CCL25-driven migration.\",\n      \"evidence\": \"PI3K inhibitor and in vivo xenograft with CCL25 neutralization; GTPase assays and ROCK inhibitor (Y-27632) in chemotaxis\",\n      \"pmids\": [\"20127861\", \"20855113\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Clinical relevance of CCR9-CCL25 axis in prostate cancer not validated in patient cohorts\", \"Interplay between RhoA and Rac pathways downstream of CCR9 not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CCL25 was shown to promote breast cancer invasion through CCR9-dependent upregulation of active MMPs (MMP-1, -9, -11, -13), while CCR9-KO mice revealed a protective role for the CCL25–CCR9 axis in colitis recovery by regulating DC subset balance and limiting Th1/Th17 cytokine production.\",\n      \"evidence\": \"Migration/invasion assays with anti-CCR9 neutralization and MMP ELISA; DSS colitis in CCR9−/− mice with flow cytometry and cytokine quantification\",\n      \"pmids\": [\"21344163\", \"21283540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting CCR9 signaling to MMP transcription not defined\", \"Whether CCR9-KO colitis phenotype reflects loss of CCL25-responsive regulatory cells specifically not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Myeloma cells were found to produce CCL25 as a paracrine chemoattractant for bone marrow mesenchymal stromal cells, which in turn enhance myeloma proliferation and survival via AKT/ERK, establishing a CCL25-driven stromal niche feedback loop.\",\n      \"evidence\": \"CCL25 neutralization in migration and co-culture assays; intrafemoral coengraftment; western blotting\",\n      \"pmids\": [\"22102554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of CCL25 relative to other MSC chemoattractants in myeloma bone marrow not quantified\", \"Therapeutic window for CCL25 blockade in myeloma not explored\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A scaffolding mechanism for CCL25-induced drug resistance was defined: phosphorylated ERM proteins link P-glycoprotein to F-actin in T-ALL cells, and ERM silencing disrupts this complex and restores drug sensitivity.\",\n      \"evidence\": \"Co-immunoprecipitation of p-ERM/P-gp/F-actin; shRNA-mediated ERM knockdown with P-gp functional assay in MOLT4 cells\",\n      \"pmids\": [\"23326330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relevance of ERM-P-gp scaffolding to primary patient T-ALL cells not tested\", \"Whether CCL25 directly phosphorylates ERM or acts indirectly not determined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CCL25 was found to induce Wnt5a expression via PKC in T-ALL cells, with Wnt5a then driving migration and invasion through PI3K/Akt-RhoA, revealing a secondary autocrine/paracrine amplification loop for CCL25-induced motility.\",\n      \"evidence\": \"siRNA and inhibitor knockdowns of PI3K/Akt and RhoA; western blotting for PKC and Wnt5a; confocal and SEM; mouse xenograft\",\n      \"pmids\": [\"28380463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Wnt5a induction by CCL25 not confirmed outside MOLT4/T-ALL cells\", \"Whether Wnt5a pathway operates in normal thymocyte migration unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"An unexpected endocrine role for CCL25 was established: CCL25 acts via Gαi-coupled CCR9 on pancreatic islet cells to inhibit glucose-stimulated insulin secretion by reducing cAMP, an effect blocked by the CCR9 antagonist vercirnon.\",\n      \"evidence\": \"Insulin secretion, cAMP, and apoptosis assays in primary human and mouse islets with pharmacological CCR9 antagonist\",\n      \"pmids\": [\"33058852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo metabolic phenotype of CCL25 or CCR9 deficiency not reported\", \"Source of CCL25 reaching islets in vivo not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CCL25 was shown to drive inflammatory processes in rheumatoid arthritis by stimulating FLS and monocyte migration via p38/ERK, polarizing monocytes into M1-like macrophages, and inducing osteoclastogenesis through a RANKL-independent, RANK/cathepsin K/TNF-α-dependent mechanism.\",\n      \"evidence\": \"p38 and ERK inhibitors; osteoclast differentiation assay; cytokine ELISA in RA synovial tissue-derived cells\",\n      \"pmids\": [\"33347617\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RANKL-independent osteoclastogenesis by CCL25 not confirmed in other systems\", \"Therapeutic relevance of CCR9 blockade in RA not tested in vivo\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"NF-κB was identified as a direct transcriptional regulator of CCL25 in endothelial cells, and CCL25 was shown to increase endothelial permeability by reducing tight junction proteins via P38 MAPK, linking CCL25 to vascular barrier dysfunction.\",\n      \"evidence\": \"Chromatin immunoprecipitation and luciferase assays for NF-κB binding; TEER and FITC permeability assays; P38 pathway analysis in LPS-stimulated HPMECs\",\n      \"pmids\": [\"35782530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo vascular permeability changes from CCL25 not demonstrated\", \"Relationship between NF-κB-driven endothelial CCL25 and Cdx-driven intestinal CCL25 not explored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CCL25–CCR9 interaction and selective integrin activation, the full physiological consequence of CCX-CKR/ACKR4 scavenging of CCL25, the in vivo metabolic impact of islet CCR9 signaling, and whether CCL25-targeted therapies (e.g., vercirnon) can selectively modulate gut homing without compromising thymic function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of CCL25–CCR9 complex\", \"CCX-CKR/ACKR4 functional role in CCL25 gradient shaping not established in vivo\", \"Tissue-specific therapeutic targeting strategies untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 4, 8, 22]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 7, 34]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 4, 8, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0006935\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 9, 11, 12, 14, 17, 18, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 7, 19, 25, 26, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 21, 23]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 25, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR9\",\n      \"ACKR4\",\n      \"ITGA4\",\n      \"ITGB7\",\n      \"ITGB1\",\n      \"EZR\",\n      \"MADCAM1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}